Pidnarulex

N/A

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NamePidnarulex
Drug Alias NameCX-5461
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA-directed RNA polymerase II subunit RPB1 inhibitorsDNA-directed RNA polymerase I subunit RPA1 inhibitors
TargetsDNA-directed RNA polymerase II subunit RPB1DNA-directed RNA polymerase I subunit RPA1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCylene
China Registration ClassN/A

Develop Information

Active CompaniesSenhwa Biosciences, IncNational Cancer Institute
Inactive CompaniesPeter Maccallum Cancer Centre, Australia
Active IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[9] 
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A